An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, State Key Laboratory of Biotherapy, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
2 Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, United States.
3 Department of Pharmacology, Cardiovascular Research Institute, BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, South Korea.
1 Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, State Key Laboratory of Biotherapy, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
2 Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA, United States.
3 Department of Pharmacology, Cardiovascular Research Institute, BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, South Korea.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
Editorial on the Research Topic Metabolic Regulation in the Development of Cardiovascular Diseases
References
Austin K. M., Trembley M. A., Chandler S. F., Sanders S. P., Saffitz J. E., Abrams D. J., et al. . (2019). Molecular mechanisms of arrhythmogenic cardiomyopathy. Nat. Rev. Cardiol. 16, 519–537. 10.1038/s41569-019-0200-7
-
DOI
-
PMC
-
PubMed
Bartrons R., Rodriguez-Garcia A., Simon-Molas H., Castano E., Manzano A., Navarro-Sabate A. (2018). The potential utility of PFKFB3 as a therapeutic target. Expert Opin. Ther. Targets 22, 659–674. 10.1080/14728222.2018.1498082
-
DOI
-
PubMed
Bonora M., Wieckowski M. R., Sinclair D. A., Kroemer G., Pinton P., Galluzzi L. (2019). Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nat. Rev. Cardiol. 16, 33–55. 10.1038/s41569-018-0074-0
-
DOI
-
PMC
-
PubMed
Chen H. J., Meng T., Gao P. J., Ruan C. C. (2021a). The role of brown adipose tissue dysfunction in the development of cardiovascular disease. Front. Endocrinol. 12:652246. 10.3389/fendo.2021.652246
-
DOI
-
PMC
-
PubMed